ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

NCT02264613 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Lymphoma
Peripheral T-Cell Lymphoma

Interventions

DRUG: ALRN-6924

Sponsor

Aileron Therapeutics, Inc.